Merck & Co has significantly lowered its adjusted EPS guidance for FY2026 while simultaneously raising its sales outlook for the same period. This divergence suggests a potential shift in profitability expectations despite stronger revenue projections, which could be a concern for investors focused on earnings per share.
Merck & Co (MRK) has announced a substantial reduction in its FY2026 adjusted EPS guidance, moving from a range of $5.04-$5.16 down to $2.66-$2.76. This represents a significant cut of nearly 50% at the midpoint, which is a major negative for investors. Concurrently, the company raised its FY2026 sales guidance slightly from $65.800B-$67.000B to $66.300B-$67.300B. The discrepancy between rising sales and falling EPS suggests potential margin compression, increased R&D costs, or other operational headwinds impacting profitability. This news is likely to be viewed negatively by the market in the short term, as earnings are a key driver of stock valuation. Traders should monitor MRK for potential downward pressure as the market digests the implications of significantly lower future earnings expectations.